Company Overview and News


Add PTLA
to your dashboard

Headline News

Portola Pharmaceuticals: The Ultra Long Views

2017-11-16 seekingalpha
Cerdulatinib is a stellar anticancer molecule that is highly likely to post positive trial results for various cancers. (83-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-7)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Portola Pharmaceuticals: Valuable Assets Likely To Counterbalance Management Woes

2017-11-14 seekingalpha
Despite having promising assets, management missteps over the years have provided us with attractive entry points. (22-0)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon and welcome to the Sangamo Therapeutics Teleconference to discuss Third Quarter 2017 Financial Results. This call is being recorded. (39-0)

Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles

2017-11-09 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (482-4)

Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?

2017-11-07 seekingalpha
Portola Pharma is a $3.5b market cap biopharmaceutical company with annualized revenue of ~$100m and a cash burn rate of ~$200m. (43-3)

Portola Pharmaceuticals' (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Welcome to Portola Pharmaceuticals Conference Call. This call is being recorded. At the end of the Company’s prepared remarks, we will open the call for questions and we'll provide specific instructions. (137-0)

36 Stocks For November 2017

2017-11-06 seekingalpha
Every month, we construct a theoretical long/short portfolio of stocks that demonstrates solid relative value with potential for ongoing cash flow growth and ROIC expansion. (703-1)

More Than 1,000 Partners Across 85 Countries Join World Thrombosis Day Campaign to Reduce Death and Disability from Thrombosis

2017-10-13 prnewswire
CHAPEL HILL, N.C., Oct. 13, 2017 /PRNewswire-USNewswire/ -- The World Thrombosis Day (WTD) Campaign, led by the International Society on Thrombosis and Haemostasis (ISTH), today announced that more than 1,000 partners across 85 countries are now participating in a united effort to reduce death and disability from thrombosis (commonly known as blood clots) – a more than five-fold increase since the campaign launched in 2014. (143-0)

Great Point Partners Llc - Current Holdings - Fintel.io

2017-10-10 fintel.io
Great Point Partners Llc has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 486,757,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Great Point Partners Llc's top holdings are Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) , Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) , Zogenix, Inc. (NASDAQ:ZGNX) , PTC Therapeutics, Inc. (362-10)

Partner Fund Management, L.P. - Current Holdings - Fintel.io

2017-09-30 fintel.io
Partner Fund Management, L.P. has disclosed 82 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 3,548,500,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Partner Fund Management, L.P.'s top holdings are Kite Pharma, Inc. (NASDAQ:KITE) , Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) , Puma Biotechnology Inc. (NYSE:PBYI) , SPDR Health Care Select Sector ETF (NYSE:XLV) , and Anthem, Inc. (179-2)

Move Over Yellen! It's Tax Cut Time!

2017-09-29 seekingalpha
The health care repeals effort fizzle out clearing the desk for Congress to focus on tax cuts. (590-0)

CUSIP: 737010108